BuzzRx

SEPTEMBER 26, 2022

However, now that life is pretty much back to normal in 2022, things might be different. When someone recovers from infectious diseases like the flu or COVID-19, they retain some natural immunity that protects them from future infections. The COVID mitigation measures in 2020, therefore, led to less natural immunity.

Vaccines 98

Vaccines Immunization Hospitals 98

European Pharmaceutical Review

AUGUST 16, 2022

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated version of Moderna’s COVID-19 vaccine, Spikevax, that targets two coronavirus variants as a booster. The regulator confirmed that the vaccine meets its standards of safety, quality and effectiveness. 1) and the original 2020 strain.

Vaccines 105

Vaccines Immunization 105

European Pharmaceutical Review

NOVEMBER 1, 2023

In July 2022, the World Health Organization (WHO) released its inaugural report on the pipeline of vaccines currently in development to prevent infections caused by antimicrobial resistance (AMR) bacterial pathogens. WHO referred to 61 bacterial vaccine candidates in diverse stages of clinical development.

Vaccines 115

Vaccines Immunization 115

The Checkup by Singlecare

SEPTEMBER 22, 2023

This year, there are new vaccines to help at-risk populations ward off severe sickness, including that caused by RSV. Here’s what you need to know about the new FDA-approved RSV vaccine. But young children, older adults, and individuals with weakened immune systems are at high risk of severe, potentially life-threatening RSV illness.

Vaccines 105

Vaccines Immunization Insurance FDA 105

Pharmacy Times

JUNE 23, 2022

Vaxneuvance was approved for an expanded indication by the FDA on June 22, 2022, for active immunization in children 6 weeks of age and older.

Immunization 123

Immunization Vaccines FDA 123

European Pharmaceutical Review

AUGUST 3, 2022

The COVID-19 pandemic has demonstrated the need for an improved vaccine approach to temper the serious threat of constantly mutating viruses, such as influenza and coronaviruses, on global health. Current vaccine strategies and their limitations. The adaptive immune response to a natural infection.

Vaccines 95

Vaccines Immunization 95

pharmaphorum

JANUARY 19, 2023

Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidemic Preparedness Innovations (CEPI), in order to advance the development of Vaxxas’ needle-free vaccine-patch delivery technology with preclinical testing of an mRNA vaccine patch. The agreement, worth $4.3 The agreement, worth $4.3

Vaccines 105

Vaccines Immunization 105

pharmaphorum

SEPTEMBER 22, 2022

Alexandre Le Vert, CEO and co-founder of Osivax, discusses the company’s breakthrough vaccine technology, oligoDOM, and how it’s driving the development of new influenza and SARS-CoV-2 vaccines that attack T-cells, providing a long-lasting effect. The technology.

Vaccines 97

Vaccines Immunization 97

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccines 117

Vaccines Immunization 117

European Pharmaceutical Review

FEBRUARY 14, 2023

Recently there have been several key advances in the clinical development of messenger RNA (mRNA) vaccines, including vaccines for RSV and a personalised cancer vaccine. 2 Yet according to a 2022 report by GlobalData, it is difficult to achieve high quality and highly pure mRNA via scalable manufacturing.

Vaccines 105

Vaccines Immunization FDA 105

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 98

Vaccines Immunization Documentation 98

Pharmaceutical Technology

MAY 2, 2023

4/5 Covid-19 messenger RNA (mRNA) vaccines. The expanded EUAs state that these current bivalent vaccines are now to be used for all primary and booster doses administered to individuals ages six months of age and older. 1 vaccines by both companies were revoked by the FDA in August 2022, after the BA.5

Vaccines 21

Vaccines FDA Immunization 21

European Pharmaceutical Review

DECEMBER 19, 2023

Many of today’s vaccines are produced in ready-to-inject liquid formulations that must be kept cold to maintain stability. However, this greatly complicates both the worldwide distribution and stockpiling of vaccines and other drugs. A requisite cold chain has been designed and implemented to be uninterrupted from factory to patient.

Vaccines 111

Vaccines Communication Immunization Documentation 111

Hospital Pharmacy Europe

JANUARY 25, 2023

The Joint Committee on Vaccination and Immunisation (JCVI) has advised offering Covid booster vaccinations in spring and autumn 2023 for patients deemed to be at high risk. That is why we have advised planning for further booster vaccines for persons at higher risk of serious illness through an autumn booster programme later this year.

Vaccines 98

Vaccines Immunization Hospitals 98

European Pharmaceutical Review

AUGUST 30, 2022

Pfizer has announced positive top-line data from a Phase III clinical trial (NCT05035212) investigating its bivalent RSV prefusion F vaccine candidate, RSVpreF, when administered to adults 60 years of age or older. In more severe disease with primary endpoint of LRTI-RSV defined by three or more symptoms, vaccine efficacy of 85.7

Vaccines 98

Vaccines FDA Immunization 98

European Pharmaceutical Review

AUGUST 22, 2022

THE GLOBAL outbreak of the COVID-19 pandemic triggered an urgent need to protect people’s lives and livelihoods and the healthcare community recognised quite early that vaccines were the best solution to this crisis. Novel biotechnology platforms for vaccine development.

Vaccines 98

Vaccines Immunization 98

DiversifyRx

OCTOBER 5, 2022

Here are the 10 most exciting companies I saw at the 2022 NCPA annual convention. NCPA held its 2022 annual convention in Kansas City. Many people are curious to know if their antibody levels are high or low and how they change after a vaccine booster or a sickness. NCPA Annual Convention 2022 Wrap Up.

Independent Pharmacies 98

Independent Pharmacies Vaccines Compounding Immunization 98

Drug Topics

NOVEMBER 3, 2023

By way of natural immunity, vaccination, and behavior change, the majority of the 30,861 documented cases and 54 deaths were confined to 2022, and the epidemic curve portrays a picture of success.

Documentation 98

Documentation Immunization Vaccines 98

European Pharmaceutical Review

JANUARY 23, 2023

We are extremely pleased that our cancer vaccine candidate EVX-01 has received the FDA fast track designation, as it enables a potentially faster approval of the vaccine,” stated Per Norlén, CEO at Denmark-based Evaxion. The FTD is for EVX-01, in combination with Keytruda ® for patients with metastatic melanoma (MM). ”We Moderna, Inc.

Immunization 124

Immunization Vaccines FDA 124

European Pharmaceutical Review

AUGUST 26, 2022

Moderna has filed patent infringement lawsuits alleging that Pfizer and BioNTech’s COVID-19 vaccine Comirnaty ® infringes patents Moderna filed between 2010 and 2016 covering its foundational messenger RNA (mRNA) technology. Pfizer and BioNTech copied this technology, without Moderna’s permission, to make Comirnaty,” said Moderna.

Vaccines 98

Vaccines Immunization 98

Digital Pharmacist

OCTOBER 26, 2022

On October 7 th , 2022 the U.S. Children aged 2 months of age or younger are not eligible for the Tdap vaccine. The lack of solid data around the effectiveness and safety of the Tdap vaccine on the newborn itself was what led to further research. formulation of the vaccine, except that the non-U.S. Background of Boostrix.

Vaccines 98

Vaccines FDA Hospitals Immunization 98

pharmaphorum

SEPTEMBER 3, 2021

Pfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson & Johnson as the companies strive to bring the first licensed shot to market. At its recent business update, GSK said it was anticipating peak sales of more than $4 billion for its vaccine if approved.

Vaccines 88

Vaccines Immunization 88

pharmaphorum

SEPTEMBER 15, 2020

billion) order for up to 190 million doses of a coronavirus vaccine in development at French company Valneva. The new deal firms up an earlier agreement in principle with the UK in July that covered up to 100 million doses of VLA2001 , a purified inactivated SARS-CoV-2 vaccine that is expected to require a two-dose vaccination regimen.

Vaccines 80

Vaccines Immunization 80

pharmaphorum

JANUARY 13, 2022

Preliminary data from an ongoing trial of AstraZeneca’s COVID-19 vaccine Vaxzevria has shown that a booster dose stimulates an increase in antibodies against Omicron, as well as other variants of the virus, including Alpha, Beta, Delta, and Gamma. billion doses administered. That’s only a little shy of the 2.6

Vaccines 98

Vaccines Immunization 98

pharmaphorum

DECEMBER 6, 2021

A trial of booster vaccinations to protect against COVID-19 has shown that the jab significantly strengthens the body’s T-cell immunity against the disease. Several COVID-19 vaccines were used in the trial – all were administered via intramuscular injection into the upper arm.

Immunization 52

Immunization Vaccines Hospitals 52

pharmaphorum

AUGUST 10, 2021

BioNTech has suggested that giving booster doses of its current Comirnaty (BNT162b2) COVID-19 vaccine may be a preferable strategy to modifying the Pfizer-partnered shot. billion doses this year with more than 1 billion already booked in for 2022. billion doses this year with more than 1 billion already booked in for 2022.

Vaccines 116

Vaccines Immunization 116

Hospital Pharmacy Europe

JULY 10, 2024

The UK is switching to a different pertussis vaccine for pregnant women following advice from the Joint Committee on Vaccination and Immunisation. Analysis showed antibody levels to polio type 2 were most affected by the maternal vaccination.

Vaccines 59

Vaccines Immunization Hospitals 59

STAT

OCTOBER 8, 2024

appeals court ruled 2-1 that Merck is immune from an antitrust lawsuit accusing it of misleading regulators about the effectiveness of its mumps vaccine in order to ward off competition, Reuters says. A group of doctors and medical practices claimed they overpaid for the vaccine, which was the only mumps shot in the U.S.

Compounding 99

Compounding FDA Compounding Pharmacies Vaccines 99

Digital Pharmacist

AUGUST 21, 2023

The most effective preventive measure against the flu is getting an annual flu vaccine. Getting Vaccinated for the Flu The CDC says ideally, everyone who is eligible for a flu vaccine should be vaccinated by the end of October – the ideal time to get vaccinated being September or October.

Vaccines 98

Vaccines Communication Immunization 98

pharmaphorum

DECEMBER 2, 2021

Health and Social Care Secretary, Sajid Javid, announced the move as researchers race to uncover the effect of existing vaccines on the Omicron variant, which was first identified by scientists in South Africa. Up to 60 million doses of Moderna’s vaccine, which may include authorised booster doses, were given the green light.

Vaccines 52

Vaccines Immunization 52

Hospital Pharmacy Europe

JULY 10, 2024

The UK is switching to a different pertussis vaccine for pregnant women following advice from the Joint Committee on Vaccination and Immunisation. Analysis showed antibody levels to polio type 2 were most affected by the maternal vaccination.

Vaccines 52

Vaccines Immunization Hospitals 52

European Pharmaceutical Review

DECEMBER 22, 2022

The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category” The term ‘mRNA’ has become commonplace globally. The success of mRNA vaccines against SARS-CoV-2 has quickly catapulted mRNA therapeutics as a disruptive, expanding drug category.

Vaccines 116

Vaccines Immunization Hospitals 116

pharmaphorum

AUGUST 16, 2022

Following the success of LNP-mRNA vaccines, we have seen an influx of novel types of lipids based nanocarriers over the last 12 months, progress has been made to minimize immuno-toxicity challenges – from maximizing therapeutic window to fine-tuning the immune response. . Download the full event guide to find out more.

Immunization 52

Immunization Vaccines 52

Pharmaceutical Technology

JANUARY 19, 2023

The Korean Ministry of Food and Drug Safety (KMFDS) has granted expanded approval to Novavax partner SK bioscience for the Covid-19 vaccine, Nuvaxovid (NVX-CoV2373), for use as a booster dose in adults aged 18 and above. Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain.

Vaccines 59

Vaccines Immunization 59

Hospital Pharmacy Europe

NOVEMBER 24, 2022

A fentanyl vaccine induced significant antibody levels and reduced brain levels of the drug and could be of value in opiate use disorder. The principle is simple: a conjugate vaccine is designed to elicit an immune response to the abused opioid (e.g., Fentanyl vaccine effectiveness. Pharmaceutics 2022.

Vaccines 59

Vaccines Immunization Hospitals 59

Roots Analysis

MARCH 16, 2023

It is worth noting that several companies have begun to develop mRNA-based cancer immunotherapies and vaccines for infectious diseases. mRNA Therapeutics and Vaccines Delivery Routes Efficient delivery of both therapeutic and vaccine candidates plays a key role in ensuring the effective expression and presentation of antigens.

Vaccines 52

Vaccines Immunization 52

pharmaphorum

JANUARY 25, 2022

Pfizer and partner BioNTech have started their clinical trial of a new version of their COVID-19 vaccine that has been specifically designed to protect against the Omicron variant. They have said that even if they do need to switch to producing a new version there will be no change expected to their four billion dose capacity for 2022.

Vaccines 98

Vaccines Immunization 98